Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

Griessbach, Alexandra; Chammartin, Frédérique; Abela, Irene A; Amico, Patrizia; Stoeckle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Audigé, Annette; Mueller, Nicolas J; Rauch, Andri; Günthard, Huldrych F; Koller, Michael T; Trkola, Alexandra; Epp, Selina; Amstutz, Alain; Schönenberger, Christof M; Taji Heravi, Ala; Kusejko, Katharina; Bucher, Heiner C; Briel, Matthias; Speich, Benjamin; Swiss HIV Cohort Study; Swiss Transplant Cohort Study

doi:10.1093/ofid/ofad150

Scientific article

English

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

ContributorsGriessbach, Alexandra

; Chammartin, Frédérique; Abela, Irene A; Amico, Patrizia; Stoeckle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Audigé, Annette; Mueller, Nicolas J; Rauch, Andri; Günthard, Huldrych F; Koller, Michael T; Trkola, Alexandra; Epp, Selina; Amstutz, Alain

; Schönenberger, Christof M; Taji Heravi, Ala; Kusejko, Katharina

; Bucher, Heiner C; Briel, Matthias

; Speich, Benjamin

; Swiss HIV Cohort Study; Swiss Transplant Cohort Study

Published inOpen forum infectious diseases, vol. 10, no. 4, ofad150

Publication date2023-04

First online date2023-03-30

Abstract

Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).

Keywords

HIV
Organ transplant
SARS-CoV-2
Vaccine
Randomized trial

Affiliation entities

Research groups

Funding

Citation (ISO format)

GRIESSBACH, Alexandra et al. Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2). In: Open forum infectious diseases, 2023, vol. 10, n° 4, p. ofad150. doi: 10.1093/ofid/ofad150

Article (Published version)

CC BY-NC-ND

Identifiers

PID : unige:180662
DOI : 10.1093/ofid/ofad150
PMID : 37035486
PMCID : PMC10077822

Additional URL for this publicationhttps://academic.oup.com/ofid/article/10/4/ofad150/7095674

Journal ISSN2328-8957

147views

121downloads

Creation24/09/2024 10:29:23

First validation09/10/2024 15:06:33

Update10/02/2026 08:04:22

Status update10/02/2026 08:04:22

Last indexation10/02/2026 08:05:19

Archive ouverte UNIGE

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

Technical informations